For healthcare professionals only
This promotional website has been developed, organised and funded by Boehringer Ingelheim.
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.
Prescribing information for United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.
Renal considerations in type 2 diabetes
Renal impairment considerations in type 2 diabetes prescribing
Pharmacy modules
Hypoglycaemia and type 2 diabetes
Renal function decline and type 2 diabetes
Type 2 diabetes in a frail older person
Watch the most recent webinar
Initiated and funded by Boehringer Ingelheim
PC-GB-110175 | July 2024
Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control
The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.
Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].
PC-GB-108643 V7 | August 2025
